News | June 23, 2026
Teva closes $700M Emalex acquisition
Bolstering neuroscience push with late-stage Tourette therapy
Bolstering neuroscience push with late-stage Tourette therapy
The accrued data from the Phase 3 study suggest that the baseline characteristics of the enrolled patients are consistent with those observed in previous studies
In the new study, scientists at the University of Virginia used gene-editing techniques to modify GLP-1 receptors in mice to make them more humanlike
The agreement could rise to $900 million if key commercial milestones are met
The company doses first patient in US study of Deraphan, as Dolby Ventures joins €53M Series B to support neuropsychiatric innovation
The conditional, time-limited approval comes through a joint effort with RACTHERA, a joint venture in which Sumitomo Chemical holds a 66.6% stake and Sumitomo Pharma holds 33.4%
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
TED?A9 is part of S.Biomedics’ expanding pipeline of stem-cell-based therapies, developed using the company’s proprietary targeted embryonic stem cell differentiation platform
The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
ALTO-207 combines pramipexole, a dopamine D3-preferring D3/D2 agonist approved for Parkinson’s disease
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
